Nesiritide: New hope for acute heart failure syndromes?

John C. Burnett

doi:10.1093/eurheartj/sui010

Nesiritide: New hope for acute heart failure syndromes?

John C. Burnett

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

B-type natriuretic peptide (BNP) is a peptide hormone that exerts cardiac, renal, and hormonal effects, and is produced by the myocardium as part of the compensatory response of the failing heart. The therapeutic benefits of exogenous BNP administration to patients with acute heart failure syndromes have been demonstrated, and recombinant human BNP (nesiritide) was licensed in the USA for the treatment of this condition in 2001. Recent studies have also found that the beneficial effects of BNP in patients with heart failure extend beyond haemodynamics, to include natriuretic, renoprotective, and anti-remodelling properties. New therapeutic opportunities for BNP are also under investigation, including the possibility of long-term use in patients with chronic congestive heart failure.

Original language	English (US)
Pages (from-to)	B25-B30
Journal	European Heart Journal, Supplement
Volume	7
Issue number	B
DOIs	https://doi.org/10.1093/eurheartj/sui010
State	Published - Apr 2005

Keywords

Acute disease
B-type natriuretic peptide
Congestive heart failure
Pathophysiology/prevention and control/therapy
Pharmacotherapy

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1093/eurheartj/sui010

Cite this

@article{359afa1ec90d49ef9d36c2afb0c911e5,

title = "Nesiritide: New hope for acute heart failure syndromes?",

abstract = "B-type natriuretic peptide (BNP) is a peptide hormone that exerts cardiac, renal, and hormonal effects, and is produced by the myocardium as part of the compensatory response of the failing heart. The therapeutic benefits of exogenous BNP administration to patients with acute heart failure syndromes have been demonstrated, and recombinant human BNP (nesiritide) was licensed in the USA for the treatment of this condition in 2001. Recent studies have also found that the beneficial effects of BNP in patients with heart failure extend beyond haemodynamics, to include natriuretic, renoprotective, and anti-remodelling properties. New therapeutic opportunities for BNP are also under investigation, including the possibility of long-term use in patients with chronic congestive heart failure.",

keywords = "Acute disease, B-type natriuretic peptide, Congestive heart failure, Pathophysiology/prevention and control/therapy, Pharmacotherapy",

author = "Burnett, {John C.}",

year = "2005",

month = apr,

doi = "10.1093/eurheartj/sui010",

language = "English (US)",

volume = "7",

pages = "B25--B30",

journal = "European Heart Journal, Supplement",

issn = "1520-765X",

publisher = "Oxford University Press",

number = "B",

}

TY - JOUR

T1 - Nesiritide

T2 - New hope for acute heart failure syndromes?

AU - Burnett, John C.

PY - 2005/4

Y1 - 2005/4

N2 - B-type natriuretic peptide (BNP) is a peptide hormone that exerts cardiac, renal, and hormonal effects, and is produced by the myocardium as part of the compensatory response of the failing heart. The therapeutic benefits of exogenous BNP administration to patients with acute heart failure syndromes have been demonstrated, and recombinant human BNP (nesiritide) was licensed in the USA for the treatment of this condition in 2001. Recent studies have also found that the beneficial effects of BNP in patients with heart failure extend beyond haemodynamics, to include natriuretic, renoprotective, and anti-remodelling properties. New therapeutic opportunities for BNP are also under investigation, including the possibility of long-term use in patients with chronic congestive heart failure.

AB - B-type natriuretic peptide (BNP) is a peptide hormone that exerts cardiac, renal, and hormonal effects, and is produced by the myocardium as part of the compensatory response of the failing heart. The therapeutic benefits of exogenous BNP administration to patients with acute heart failure syndromes have been demonstrated, and recombinant human BNP (nesiritide) was licensed in the USA for the treatment of this condition in 2001. Recent studies have also found that the beneficial effects of BNP in patients with heart failure extend beyond haemodynamics, to include natriuretic, renoprotective, and anti-remodelling properties. New therapeutic opportunities for BNP are also under investigation, including the possibility of long-term use in patients with chronic congestive heart failure.

KW - Acute disease

KW - B-type natriuretic peptide

KW - Congestive heart failure

KW - Pathophysiology/prevention and control/therapy

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=17144376401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144376401&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/sui010

DO - 10.1093/eurheartj/sui010

M3 - Review article

AN - SCOPUS:17144376401

SN - 1520-765X

VL - 7

SP - B25-B30

JO - European Heart Journal, Supplement

JF - European Heart Journal, Supplement

IS - B

ER -

Nesiritide: New hope for acute heart failure syndromes?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this